Literature DB >> 18540832

Light at night, chronodisruption, melatonin suppression, and cancer risk: a review.

Russel J Reiter1, Dun-Xian Tan, Ahmet Korkmaz, Thomas C Erren, Claus Piekarski, Hiroshi Tamura, Lucien C Manchester.   

Abstract

Light exposure during the night is becoming progressively more common throughout the world, particularly in areas where electricity is commonly used. Also, the availability of artificial light has allowed humans to work or recreate throughout the 24-hour day. Based on photographs taken of the Earth from outer space, it is also apparent that true darkness is disappearing. For years it was assumed that polluting the daily dark period with light was inconsequential in terms of animal/human physiology. That assumption, however, has proven incorrect. Light at night has two major physiological actions, i.e., it disrupts circadian rhythms and suppresses the production of melatonin by the pineal gland. Moreover, both these changes are light intensity and wavelength dependent. Both human epidemiological and experimental studies on animals have documented that a potential negative consequence of chronodisruption and nocturnal melatonin inhibition is cancer initiation and growth. In epidemiological studies, the frequency of each of the following cancers has been reportedly increased in individuals who routinely work at night or whose circadian rhythms are disrupted for other reasons (e.g., due to jet lag): breast, prostate, endometrial, and colorectal. Likewise, in experimental animals, cancer growth is exaggerated when the animals are repeatedly phase advanced (as occurs during easterly flights) or exposed to light at night. A variety of mechanisms have been examined to explain how the suppression of melatonin exaggerates cancer risk. Mechanistically, how chronodisruption (without a consideration of melatonin suppression) would enhance cancer frequency is less clear. In addition to cancer, there may be other diseases that result from the chronic suppression of melatonin by light at night.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18540832     DOI: 10.1615/critrevoncog.v13.i4.30

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  49 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 2.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

Review 3.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.

Authors:  Brittney Jung-Hynes; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-01       Impact factor: 13.007

4.  Ontogeny and aging of the distal skin temperature rhythm in humans.

Authors:  H Batinga; A Martinez-Nicolas; M Zornoza-Moreno; M Sánchez-Solis; E Larqué; M T Mondéjar; M Moreno-Casbas; F J García; M Campos; M A Rol; J A Madrid
Journal:  Age (Dordr)       Date:  2015-03-27

5.  Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells.

Authors:  Brittney Jung-Hynes; Wei Huang; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-05-27       Impact factor: 13.007

Review 6.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

7.  Influence of Daytime LED Light Exposure on Circadian Regulatory Dynamics of Metabolism and Physiology in Mice.

Authors:  Robert T Dauchy; David E Blask; Aaron E Hoffman; Shulin Xiang; John P Hanifin; Benjamin Warfield; George C Brainard; Murali Anbalagan; Lynell M Dupepe; Georgina L Dobek; Victoria P Belancio; Erin M Dauchy; Steven M Hill
Journal:  Comp Med       Date:  2019-09-20       Impact factor: 0.982

8.  MicroRNAs in the pineal gland: miR-483 regulates melatonin synthesis by targeting arylalkylamine N-acetyltransferase.

Authors:  Samuel J H Clokie; Pierre Lau; Hyun Hee Kim; Steven L Coon; David C Klein
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

9.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 10.  Healthy clocks, healthy body, healthy mind.

Authors:  Akhilesh B Reddy; John S O'Neill
Journal:  Trends Cell Biol       Date:  2009-11-16       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.